Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation

measurable disease
fludarabine
  • 0 views
  • 22 Jan, 2022
  • 2 locations
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

of an antibody called anti-CD138. This antibody floats around in the blood and can detect and stick to cancer cells called multiple myeloma cells because they have a substance on the outside of the

bacterial infection
fludarabine
chemotherapy regimen
tumor cells
corticosteroids
  • 25 views
  • 29 Dec, 2021
  • 1 location
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After …

proteasome inhibitor
immunotherapeutic agent
daratumumab
lymphoma
neutrophil count
  • 5 views
  • 02 Jan, 2022
  • 35 locations
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR

heparin
cancer
calcium
bone marrow procedure
revlimid
  • 15 views
  • 22 Jan, 2022
  • 1 location
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy …

daratumumab
calcium
bone marrow procedure
neutrophil count
bcma
  • 10 views
  • 27 Dec, 2021
  • 7 locations
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells

vasectomy
cell transplantation
daratumumab
chemotherapy regimen
neutrophil count
  • 2 views
  • 05 Jan, 2022
  • 3 locations
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the

platelet count
cell transplantation
neutrophil count
refractory multiple myeloma
  • 0 views
  • 10 Jan, 2022
  • 7 locations
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent

dexamethasone
refractory multiple myeloma
bone marrow procedure
measurable disease
lenalidomide
  • 0 views
  • 05 Jan, 2022
  • 2 locations
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified

human chorionic gonadotropin
refractory multiple myeloma
  • 0 views
  • 11 Jan, 2022
  • 4 locations
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

human chorionic gonadotropin
carfilzomib
measurable disease
lenalidomide
  • 0 views
  • 09 Jan, 2022
  • 3 locations